
A
WT
BAX, BAK, BOK k.o.
BAX
GAPDH
BAK
GAPDH
BOK
GAPDH
B
WT
BAX, BAK k.o.
BAX
GAPDH
BAK
GAPDH
BOK
GAPDH
C
Fractional viability
PT
PS d1
PS d7
μM ABT737 (+ 2xS6)
D
A549
metastatic ratio (%)
PS
PT
E
HT29 PT
HT29 PS
Fractional viability
ns
****
MOCK
Oxaliplatin
Irinotecan
Etoposide
Vemurafenib
F
HT29 PT, RSL3 (IC50 >10 μM)
HT29 PS, RSL3 (IC50 3.2 μM)
Fractional viability
RSL3 (μM)
G
RSL3 (μM)
***
PT
PS
H
MFI c11-bodipy
PT
PS
MOCK
RSL3
RSL3, DFO
I
fold change (2^ddct)
WT, PT
WT, PS
CHAC1
GCLC
J
ABT737/ S6
Erlotinib
Paclitaxel
KEGG
Cytokine-cytokine receptor interaction
NF-kappa B signaling pathway
Viral protein interaction with cytokine (-receptor)
Glycosaminoglycan biosynthesis
ECM_receptor interaction
Rheumatoid arthritis
Inflammatory bowel disease
MAPK signaling pathway
Fatty acid metabolism
Terpenoid backbone biosynthesis
DNA replication
Steroid biosynthesis
Reactome
Interleukin10 signaling
Interleukin4 and Interleukin13 signaling
Regulation of TNFR1 signaling
Integrin cell surface interactions
Extracellular matrix organization
Mismatch Repair
Fatty acyl_CoA biosynthesis
Metabolism of steroids
DNA strand elongation
Regulation of cholesterol biosynthesis by SREBP (SREBF)
Activation of gene expression by SREBF (SREBP)
Cholesterol biosynthesis
NES